Congruence Therapeutics to Present Preclinical Characterization of its MC4R Corrector Development Candidate CGX-926 for Genetic Obesity at ObesityWeek 2025

– Presentation highlights in vitro activity across a spectrum of clinically-relevant variants as well as in vivo reduction of body weight and hyperphagia in MC4R-deficient Mutant Mice – MONTREAL, Nov. 6, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology...